Vivalis SA of Nantes France has signed two commercial license agreements with the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) of Kumamoto, Japan. The agreements cover Vivalis’ proprietary EB66 cell line, for the production of several veterinary and human vaccines, including Vaccinia virus-based recombinant human vaccines and inactivated and live viral human vaccines.
“This agreement with Kaketsuken, a leading company in the fields both human and animal vaccines in Japan, constitutes an additional and significant industrial endorsement of Vivalis EB66 technology,” said Franck Grimaud, Vivalis CEO. “With a portfolio of 21 licenses, the EB66 cell line is reinforcing its position as a new standard cell substrate for the manufacturing of biological products.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
